Navigation Links
Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Date:12/7/2011

MINNEAPOLIS, Dec. 7, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the Oppenheimer 22nd Annual Healthcare Conference at 2:10 PM ET on Tuesday, December 13, 2011 at The Waldorf Astoria Hotel in New York.

Attendance at the conference is by invitation only.  A live audio webcast of the presentation will be broadcast via the Internet.  Those interested in listening to the webcast may access it at http://www.veracast.com/webcasts/opco/healthcare2011/90116388.cfm or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

 

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.


 

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

 

EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Chris Gale (Media), 646.201.5431

 


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Uroplasty Reports Third Quarter Fiscal 2009 Results
2. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
3. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
4. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
5. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
6. Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
8. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. VIVUS to Present at the Deutsche Bank BioFEST Conference
10. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
11. Verenium to Present at Baird Clean Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):